• Arbeitsgruppenleiter:in: Prof. Dr. Georg Heß

• Forschungsschwerpunkte:
  
  Frühe klinische Studien:
  Maligne Lymphome, Fokus auf klinischen Studien, epidemiologischen Langzeitbeoachtungen, QoL, MRD

• Fünf wichtigste Publikationen:
  
  Hess G, Herbrecht R, Romaguera J, et al: Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27:3822-9, 2009.
  
  Hess G, Keller U, Scholz CW, et al: Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma. Leukemia 29:1695-701, 2015.
  
  Hess G, Rule S, Jurczak W, et al: Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus. Leuk Lymphoma:1-9, 2017.
  
  Morschhauser F, Bouabdallah K, Stilgenbauer S, et al: Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study. Haematologica, 2020.
  
  Viardot A, Hess G, Bargou RC, et al: Durability of complete response after blinatumomab therapy for relapsed/refractory diffuse large B-cell lymphoma. Leuk Lymphoma:1-4, 2020.

• Ansprechpartner:in:
  
  Dr. rer. nat. Anke Ohler
  E-Mail: anke.ohler@unimedizin-mainz.de